Sitagliptin Mitigates Total Body Irradiation-Induced Hematopoietic Injury in Mice. (25th July 2020)

• Record Type: Journal Article
• Authors: Wang, Meifang; Dong, Yinping; Wu, Jing; Li, Hongyan; Zhang, Junling; Lu, Lu; Zhang, Yuanyang; Zhou, Zewei; Fan, Saijun; Li, Deguan; Meng, Aimin
• Other Names: Saso Luciano Academic Editor.
• Is Part Of: Oxidative medicine and cellular longevity. Volume 2020(2020)
• Publication Date: 2020-07-25
• Subjects: Oxidative stress -- Periodicals; Cells -- Aging -- Periodicals; Cells -- Aging; Oxidative stress; Oxidative Stress -- Periodicals; Cell Aging -- Periodicals; Periodicals; 611.0181
• DOI: 10.1155/2020/8308616
• Languages: English
• ISSNs: 1942-0900

Abstract

Abstract : Sitagliptin, an inhibitor of the dipeptidyl peptidase IV (DPP4), has been implicated in the regulation of type 2 diabetes. However, the role and mechanism of sitagliptin administration in total body irradiation (TBI)- induced hematopoietic cells injury are unclear. In this study, we demonstrated that sitagliptin had therapeutic effects on hematopoietic damage, which protected mice from 7.5 Gy TBI-induced death, increased the numbers and colony formation ability of hematopoietic cells. These therapeutic effects might be attributed to the inhibition of NOX4-mediated oxidative stress in hematopoietic cells, and the alleviation of inflammation was also helpful. Therefore, sitagliptin has potential as an effective radiotherapeutic agent for ameliorating TBI-induced hematopoietic injury.